These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 17126478)

  • 1. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
    Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C
    Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
    Das S; Roth CP; Wasson LM; Vishwanatha JK
    Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas.
    Shida T; Furuya M; Nikaido T; Kishimoto T; Koda K; Oda K; Nakatani Y; Miyazaki M; Ishikura H
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):450-8. PubMed ID: 15701827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer.
    Alberti I; Barboro P; Barbesino M; Sanna P; Pisciotta L; Parodi S; Nicolò G; Boccardo F; Galli S; Patrone E; Balbi C
    J Cell Biochem; 2000 Sep; 79(3):471-85. PubMed ID: 10972984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
    Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
    Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
    Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
    Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine differentiation in prostate adenocarcinoma.
    Sciarra A
    Eur Urol; 2007 Nov; 52(5):1373. PubMed ID: 17985422
    [No Abstract]   [Full Text] [Related]  

  • 8. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
    Mariani S; Salvatori L; Basciani S; Arizzi M; Franco G; Petrangeli E; Spera G; Gnessi L
    J Urol; 2006 Jun; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR2 expression correlates with prostate cancer progression.
    Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
    J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgG gene expression and its possible significance in prostate cancers.
    Liu Y; Chen Z; Niu N; Chang Q; Deng R; Korteweg C; Gu J
    Prostate; 2012 May; 72(6):690-701. PubMed ID: 22430367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
    Yu DS; Hsieh DS; Chen HI; Chang SY
    J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
    Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
    Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor 17 is over-expressed in human prostate cancer.
    Heer R; Douglas D; Mathers ME; Robson CN; Leung HY
    J Pathol; 2004 Dec; 204(5):578-86. PubMed ID: 15538740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
    Rehman I; Azzouzi AR; Cross SS; Deloulme JC; Catto JW; Wylde N; Larre S; Champigneuille J; Hamdy FC
    Hum Pathol; 2004 Nov; 35(11):1385-91. PubMed ID: 15668896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer.
    Koike H; Sekine Y; Kamiya M; Nakazato H; Suzuki K
    Urology; 2008 Dec; 72(6):1229-33. PubMed ID: 18336887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of basal cell keratins in human prostate cancer metastases and cell lines.
    van Leenders GJ; Aalders TW; Hulsbergen-van de Kaa CA; Ruiter DJ; Schalken JA
    J Pathol; 2001 Dec; 195(5):563-70. PubMed ID: 11745692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
    Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
    Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
    Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
    Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.